



Imaging biomarkers are the key to detecting and treating cancer

Press Release

MEDIAN Technologies to Participate in the 2013 World Conference on Lung Cancer in Sydney

- ✓ The MEDIAN Technologies team will be available at **Booth 1506** to give demonstrations of MEDIAN's advanced medical imaging solutions for screening, diagnosing, and monitoring lung cancer patients in clinical routine and clinical trials.
- ✓ MEDIAN Technologies coauthored a poster publication presented by Saga University, Japan: "*Evaluation of a Cloud-based Solution for Local Imaging Evaluations in Clinical Trials for Lung Cancer*" scheduled October, 28th 9:30 to 4:30 in the Exhibit Hall, Ground level of the Sydney Convention and Exhibition Centre.

SOPHIA ANTIPOLIS, France – October 24, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, today announced its participation in the World Conference on Lung Cancer (WCLC2013), to be held October 27-30, in Sydney, Australia.

During the WCLC2013, the world's premier conference on lung cancer organized every two years by the International Association for the Study of Lung Cancer –IASLC-, MEDIAN's team will be available at Booth 1506 to give demonstrations of MEDIAN's advanced medical imaging solutions LMS for screening, diagnosing, and monitoring cancer patients in clinical routine and clinical trials. MEDIAN will present its offering to develop and monitor CT Lung Cancer Screening programs regionally.

In parallel, MEDIAN Technologies has coauthored a poster publication presented by Saga University, Japan: "*Evaluation of a Cloud-based Solution for Local Imaging Evaluations in Clinical Trials for Lung Cancer*" scheduled October, 28th, 9:30 to 4:30 in the Exhibit Hall of the Sydney Convention and Exhibition Centre. The abstract of the study can be downloaded here: <http://abstracts.webges.com/wclc2013/myitinerary> (Abstract number P1.19-004). The goal of the study is to evaluate a cloud-based paradigm implementing software solutions and services that standardize imaging evaluations among international investigator sites. The study shows the feasibility of imaging evaluations based on cloud services for a clinical study involving multiple international sites. The study was performed using MEDIAN's Lesion Management Solutions (LMS) and MEDIAN's Clinical Trial Imaging Services (CTIS).

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the US. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world's largest CRO to offer integrated imaging services for clinical trials to customers worldwide.



Imaging biomarkers are the key to detecting and treating cancer

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO

+ 33 492 906 582

fredrik.brag@mediantechnologies.com

Press

ALIZE RP

Caroline Carmagnol

+ 33 664 189 959

caroline@alizerp.com

Christian Berg

+ 33 170 225 386

christian@alizerp.com